FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment Pliant’s proprietary selective, targeted, integrin-mediated delivery platform demonstrates encouraging initial preclinical results Strengthened leadership team with appointments of David Raben, M.D., as Chief Medical Officer and Craig Blanchette, Ph.D., as Senior Vice President, Research (RNAi) SOUTH SAN FRANCISCO, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage bi ...